Optus Pharmaceutical applies for Korean MFDS approval for presbyopia treatment 'Clothy'
Predicted impact: Low
Presbyterian drug approval filing already reported; commercialization is targeted for 2028
Optus Pharmaceutical옵투스제약
131030 · KOSDAQ · ₩131030 · 옵투스제약
₩5,750▼ ₩190 (3.20%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −20.03%
- Market cap
- ₩101B
- Enterprise value
- ₩94B
- P/E
- 8.2×
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- 6.9%
- Net margin
- 13.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−72.3% from the high
₩4,610Today: ₩5,740 – ₩5,880₩20,750
Returns
- 1W−6.5%
- 1M−1.5%
- 3M+6.9%
- 6M−40.1%
- YTD−16.4%
- 1Y−15.6%
- Volume today
- 11,454
- 0.3× the 20-day average
- Traded today
- ₩66M
- Listed shares
- 17,646,590
- EPS (12 months)
- ₩703
- Earnings yield 12.2%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: A regulatory filing for a new drug is a positive step, but approval is not yet granted. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-0.2% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Optus Pharmaceutical stock overview
Optus Pharmaceutical (옵투스제약, KRX: 131030) is listed on KOSDAQ, in the Biotech & Pharma sector. Optimus Pharma is a Korean pharmaceutical company focused on developing, manufacturing, and selling eye-disease treatments, including products for dry eye, glaucoma, and anti-inflammatory therapy. Its shares closed at ₩5,750 on Oct 26, 2026, down 3.20% on the day, giving it a market value of ₩101B.
Key facts
- Market cap
- ₩101B
- Sector
- Biotech & Pharma
- Latest price change
- −3.20%
- As of
- Oct 26, 2026
- Main business
- Optimus Pharma is a Korean pharmaceutical company focused on developing, manufacturing, and selling eye-disease treatments, including products for dry eye, glaucoma, and anti-inflammatory therapy.
Quick answers about Optus Pharmaceutical
- What does Optus Pharmaceutical do?
- Optimus Pharma is a Korean pharmaceutical company focused on developing, manufacturing, and selling eye-disease treatments, including products for dry eye, glaucoma, and anti-inflammatory therapy. Its main products include preservative-free eye drops such as Tearin P eye drops and Hamelon eye drops, and it produces single-use eye drops at its Osong plant in Chungcheongbuk-do, with its Suwon research center working on quality improvement and new products. Its business divisions cover ophthalmic prescription drugs sold to clinics and hospitals, contract manufacturing and development for pharmaceutical clients, global exports of eye drops, and the OUE& over-the-counter eye care brand.
- What is the market cap of Optus Pharmaceutical?
- The market capitalisation of Optus Pharmaceutical was ₩101B at the close on Oct 26, 2026.
- Who are the largest shareholders of Optus Pharmaceutical?
- According to the latest official filings, the largest reported holders are Korea Securities Finance (4.03%, as of Oct 10, 2025); Yoon Dae-in (1.13%, as of Jun 12, 2026); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.04%, as of Jul 31, 2026).
- When is the next earnings report from Optus Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Optus Pharmaceutical filed the same report in past years, its next preliminary results is expected between Jan 24, 2026 and Nov 8, 2026.
Company profile
Optimus Pharma is a Korean pharmaceutical company focused on developing, manufacturing, and selling eye-disease treatments, including products for dry eye, glaucoma, and anti-inflammatory therapy. Its main products include preservative-free eye drops such as Tearin P eye drops and Hamelon eye drops, and it produces single-use eye drops at its Osong plant in Chungcheongbuk-do, with its Suwon research center working on quality improvement and new products. Its business divisions cover ophthalmic prescription drugs sold to clinics and hospitals, contract manufacturing and development for pharmaceutical clients, global exports of eye drops, and the OUE& over-the-counter eye care brand.
Written by AI from the company's latest annual report.
- Korean name
- 옵투스제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 심상호
- Founded
- Jul 2010
- Listed
- Dec 2010
- Listed shares
- 17,646,590
- Fiscal year ends
- Month 12
- Website
- www.optuspharm.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent news
Optus Pharmaceutical files for approval of 'Clossi', a presbyopia drug, targeting commercialization in 2028
Predicted impact: Low
Drug approval filing with commercialization targeted for 2028; small company and distant timeline.
Recent filings
See all- Amended: Major management matter relevant to investorsOct 22, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- [Corrected] New Facility Investment, etc.Jun 26, 2026
- Insider shareholding reportJun 12, 2026
- Not Designated as Unfaithful Disclosure Company (Designation Deferred)May 29, 2026
Titles in Korean until English translations are added.
Also known as: Optus Pharmaceutical / 옵투스제약 / 131030 / KRX:131030
Source: KRX statistical information